Phenotypes associated with this allele
Allelic Composition |
Zfp830tm2.2Cota/Zfp830tm2.2Cota
|
|
Genetic Background |
either: (involves: 129/Sv * 129S2/SvPas * C57BL/6) or (involves: 129/Sv * 129S2/SvPas * BALB/c * C57BL/6) |
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Zfp830tm2.2Cota mutation
(0 available);
any
Zfp830 mutation
(14 available)
|
|
|
mortality/aging
|
• mice die by implantation
|
Allelic Composition |
Zfp830tm2Cota/Zfp830tm2.2Cota
|
|
Genetic Background |
either: (involves: 129/Sv * 129S2/SvPas * C57BL/6) or (involves: 129/Sv * 129S2/SvPas * BALB/c * C57BL/6) |
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Zfp830tm2.2Cota mutation
(0 available);
any
Zfp830 mutation
(14 available)
Zfp830tm2Cota mutation
(0 available);
any
Zfp830 mutation
(14 available)
|
|
|
mortality/aging
|
• mice die by implantation
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation
(1 available);
any
Gt(ROSA)26Sor mutation
(942 available)
Zfp830tm2.1Cota mutation
(0 available);
any
Zfp830 mutation
(14 available)
Zfp830tm2.2Cota mutation
(0 available);
any
Zfp830 mutation
(14 available)
|
|
|
cellular
|
• in tamoxifen-treated fibroblasts
|
|
• proliferation of mouse embryonic fibroblasts is arrested 24 hours after tamoxifen-treatment unlike in control cells
|